"Auranofin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.
| Descriptor ID |
D001310
|
| MeSH Number(s) |
D02.691.675.249.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Auranofin".
Below are MeSH descriptors whose meaning is more specific than "Auranofin".
This graph shows the total number of publications written about "Auranofin" by people in this website by year, and whether "Auranofin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Auranofin" by people in Profiles.
-
Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization. Molecules. 2021 Jun 21; 26(12).
-
Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs. FASEB J. 2021 06; 35(6):e21651.
-
Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics*. Chemistry. 2020 Nov 26; 26(66):15140-15144.
-
The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells. Virology. 2020 08; 547:7-11.
-
Auranofin is an effective agent against clinical isolates of Staphylococcus aureus. Future Med Chem. 2019 06; 11(12):1417-1425.
-
A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer. Invest New Drugs. 2019 12; 37(6):1166-1176.
-
Auranofin and its Analogues Show Potent Antimicrobial Activity against Multidrug-Resistant Pathogens: Structure-Activity Relationships. ChemMedChem. 2018 11 20; 13(22):2448-2454.
-
Host oxidative folding pathways offer novel anti-chikungunya virus drug targets with broad spectrum potential. Antiviral Res. 2017 07; 143:246-251.
-
Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: correlation with clinical and immunological parameters and with the response to auranofin treatment. Clin Exp Rheumatol. 1994 Jul-Aug; 12(4):357-62.